Logo image of YCBD

CBDMD INC (YCBD) Stock Fundamental Analysis

NYSEARCA:YCBD - NYSE Arca - US12482W3097 - Common Stock - Currency: USD

0.43  -0.02 (-4.44%)

After market: 0.4302 +0 (+0.05%)

Fundamental Rating

2

YCBD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. YCBD has a bad profitability rating. Also its financial health evaluation is rather negative. YCBD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

YCBD had negative earnings in the past year.
YCBD had a negative operating cash flow in the past year.
In the past 5 years YCBD reported 4 times negative net income.
YCBD had a negative operating cash flow in each of the past 5 years.
YCBD Yearly Net Income VS EBIT VS OCF VS FCFYCBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of YCBD (-72.81%) is worse than 72.83% of its industry peers.
YCBD has a worse Return On Equity (-392.38%) than 79.89% of its industry peers.
Industry RankSector Rank
ROA -72.81%
ROE -392.38%
ROIC N/A
ROA(3y)-140.25%
ROA(5y)-86.1%
ROE(3y)-308.88%
ROE(5y)-187.27%
ROIC(3y)N/A
ROIC(5y)N/A
YCBD Yearly ROA, ROE, ROICYCBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

YCBD has a better Gross Margin (61.57%) than 68.48% of its industry peers.
In the last couple of years the Gross Margin of YCBD has remained more or less at the same level.
YCBD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.98%
GM growth 5Y0.07%
YCBD Yearly Profit, Operating, Gross MarginsYCBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

YCBD does not have a ROIC to compare to the WACC, probably because it is not profitable.
YCBD has more shares outstanding than it did 1 year ago.
YCBD has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, YCBD has a worse debt to assets ratio.
YCBD Yearly Shares OutstandingYCBD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
YCBD Yearly Total Debt VS Total AssetsYCBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

YCBD has an Altman-Z score of -23.35. This is a bad value and indicates that YCBD is not financially healthy and even has some risk of bankruptcy.
YCBD has a Altman-Z score of -23.35. This is amonst the worse of the industry: YCBD underperforms 87.50% of its industry peers.
YCBD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.35
ROIC/WACCN/A
WACC9.52%
YCBD Yearly LT Debt VS Equity VS FCFYCBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 0.74 indicates that YCBD may have some problems paying its short term obligations.
YCBD has a worse Current ratio (0.74) than 92.93% of its industry peers.
A Quick Ratio of 0.47 indicates that YCBD may have some problems paying its short term obligations.
YCBD has a Quick ratio of 0.47. This is amonst the worse of the industry: YCBD underperforms 95.65% of its industry peers.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.47
YCBD Yearly Current Assets VS Current LiabilitesYCBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.59% over the past year.
YCBD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.35%.
YCBD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.80% yearly.
EPS 1Y (TTM)86.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
Revenue 1Y (TTM)-19.35%
Revenue growth 3Y-24.06%
Revenue growth 5Y-3.8%
Sales Q2Q%-4.94%

3.2 Future

The Earnings Per Share is expected to grow by 38.90% on average over the next years. This is a very strong growth
YCBD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.69% yearly.
EPS Next Y71.11%
EPS Next 2Y38.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9.38%
Revenue Next 2Y9.69%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
YCBD Yearly Revenue VS EstimatesYCBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
YCBD Yearly EPS VS EstimatesYCBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for YCBD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for YCBD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YCBD Price Earnings VS Forward Price EarningsYCBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YCBD Per share dataYCBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

YCBD's earnings are expected to grow with 38.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.9%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for YCBD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CBDMD INC

NYSEARCA:YCBD (2/24/2025, 8:04:00 PM)

After market: 0.4302 +0 (+0.05%)

0.43

-0.02 (-4.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)05-13 2025-05-13
Inst Owners2.97%
Inst Owner Change-92%
Ins Owners7.54%
Ins Owner Change0%
Market Cap2.69M
Analysts82.86
Price Target2.04 (374.42%)
Short Float %10.36%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.91%
Min EPS beat(2)41.18%
Max EPS beat(2)112.65%
EPS beat(4)3
Avg EPS beat(4)37.83%
Min EPS beat(4)-13.73%
Max EPS beat(4)112.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-2.04%
Min Revenue beat(2)-7.05%
Max Revenue beat(2)2.96%
Revenue beat(4)1
Avg Revenue beat(4)-8.45%
Min Revenue beat(4)-20.58%
Max Revenue beat(4)2.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)44.94%
EPS NY rev (3m)44.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.14
P/FCF N/A
P/OCF N/A
P/B 1.37
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS3.11
BVpS0.31
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.81%
ROE -392.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.57%
FCFM N/A
ROA(3y)-140.25%
ROA(5y)-86.1%
ROE(3y)-308.88%
ROE(5y)-187.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.98%
GM growth 5Y0.07%
F-Score4
Asset Turnover1.84
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.22%
Cap/Sales 1.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.74
Quick Ratio 0.47
Altman-Z -23.35
F-Score4
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)26.48%
Cap/Depr(5y)59.22%
Cap/Sales(3y)1.56%
Cap/Sales(5y)1.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
EPS Next Y71.11%
EPS Next 2Y38.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-19.35%
Revenue growth 3Y-24.06%
Revenue growth 5Y-3.8%
Sales Q2Q%-4.94%
Revenue Next Year9.38%
Revenue Next 2Y9.69%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y60.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y86.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y91.8%
OCF growth 3YN/A
OCF growth 5YN/A